



(86) Date de dépôt PCT/PCT Filing Date: 1995/12/26
(87) Date publication PCT/PCT Publication Date: 1996/07/04
(45) Date de délivrance/Issue Date: 2008/07/08
(85) Entrée phase nationale/National Entry: 1997/06/27
(86) N° demande PCT/PCT Application No.: US 1995/017002
(87) N° publication PCT/PCT Publication No.: 1996/020273
(30) Priorité/Priority: 1994/12/27 (US08/364,600)

(51) Cl.Int./Int.Cl. *A61K 39/21* (2006.01),
C12N 7/00 (2006.01)
(72) Inventeur/Inventor:
APTE, SATEESH N., US
(73) Propriétaire/Owner:
APTE, SATEESH N., US
(74) Agent: RICHES, MCKENZIE & HERBERT LLP

(54) Titre : VACCINS DU VIRUS DE L'IMMUNODEFICIENCE HUMAINE ET AGENTS THERAPEUTIQUES CONTENANT
DES MUTANTS AMPUTES DE NEF DE VIH-1 A REPLICATION COMPROMISE
(54) Title: HUMAN IMMUNODEFICIENCY VIRUS VACCINES AND THERAPEUTICS CONTAINING REPLICATION-
IMPAIRED HIV-1 NEF-DELETION MUTANTS

(57) **Abrégé/Abstract:**

There is currently no specific immunological treatment utilizing live virus for infection by Human Immunodeficiency Virus (HIV) which is a cause of a clinical syndrome called Acquired Immunodeficiency Syndrome (AIDS). Several prior attempts have been made to develop vaccines to boost the humoral immune response to envelope and gag proteins which have been uniformly unsuccessful because of various factors including cell-to-cell propagation of the HIV and its destruction of the cell mediated immune system of the body by its cytopathic and fatal effect on T_{HELPER} (CD4) cells. The present invention describes a method of creating a recombinant HIV virus clone with its nef gene deleted. The invention further describes a method of creating an injectable suspension of the virus particles and preferred treatment protocol for patients infected with the HIV. A protocol for the prevention of wild-type HIV infection has also been described. It is believed that the preferred embodiment works by eliminating blocking of induction of IL-2 mRNA and IFN γ in lymphoid cells by the nef protein, by developing a cell mediated immune response to HIV via cytotoxic T Lymphocytes (CTL) and by competing with the wild-type HIV for potential hosts and thus increasing the likelihood of exposure of the wild-type HIV to humoral antibodies to gp120, gp41 and gag proteins.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 7/04, 15/64, 15/00, 15/09, 15/63, 15/70, 15/74, C12P 19/34, A61K 39/21	A1	(11) International Publication Number: WO 96/20273 (43) International Publication Date: 4 July 1996 (04.07.96)
(21) International Application Number: PCT/US95/17002 (22) International Filing Date: 26 December 1995 (26.12.95) (30) Priority Data: 08/364,600 27 December 1994 (27.12.94) US (71)(72) Applicant and Inventor: APTE, Sateesh, N. [IN/US]; Suite 206, 2817 Crow Canyon Road, San Ramon, CA 94583 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HUMAN IMMUNODEFICIENCY VIRUS VACCINES AND THERAPEUTICS CONTAINING REPLICATION-IMPAIRED HIV-1 NEF-DELETION MUTANTS (57) Abstract There is currently no specific immunological treatment utilizing live virus for infection by Human Immunodeficiency Virus (HIV) which is a cause of a clinical syndrome called Acquired Immunodeficiency Syndrome (AIDS). Several prior attempts have been made to develop vaccines to boost the humoral immune response to envelope and <i>gag</i> proteins which have been uniformly unsuccessful because of various factors including cell-to-cell propagation of the HIV and its destruction of the cell mediated immune system of the body by its cytopathic and fatal effect on T_{HELPER} (CD4) cells. The present invention describes a method of creating a recombinant HIV virus clone with its <i>nef</i> gene deleted. The invention further describes a method of creating an injectable suspension of the virus particles and preferred treatment protocol for patients infected with the HIV. A protocol for the prevention of wild-type HIV infection has also been described. It is believed that the preferred embodiment works by eliminating blocking of induction of IL-2 mRNA and IFNγ in lymphoid cells by the <i>nef</i> protein, by developing a cell mediated immune response to HIV via cytotoxic T Lymphocytes (CTL) and by competing with the wild-type HIV for potential hosts and thus increasing the likelihood of exposure of the wild-type HIV to humoral antibodies to gp120, gp41 and <i>gag</i> proteins.		

Title

5

"Human immunodeficiency virus vaccines and therapeutics containing replication-impaired HIV-1 *nef*-deletion mutants."

10

DESCRIPTION**BACKGROUND OF THE INVENTION**

15

1. FIELD OF THE INVENTION

This invention relates to treatment and prevention of Human Immunodeficiency Virus (HIV) by using a live genetically altered HIV virus vaccine.

20

2. DESCRIPTION OF THE PRIOR ART

To the best of this inventor's knowledge, no prior art employing a similar invention for treatment or prevention exists.

25

Human Immunodeficiency Virus (HIV) is the primary etiologic agent for the acquired immunodeficiency syndrome (AIDS). HIV exhibits high genetic variation, which results in a wide variety of biological phenotypes displayed by various strains of the virus and also by the same strain of the virus in a single patient at different times. Phenotypic heterogeneity is found in replication kinetics, susceptibility to serum neutralization, anti-viral drug resistance, induction of cytopathicity and host-cell range specificity. The two main sub-

30 types HIV-1 and HIV-2 are members of a group of closely related human and non-human primate lentiviruses which are RNA retroviruses.

Infection by the HIV leads to progressive deterioration of cell mediated immune system making the victim susceptible to a variety of opportunistic infections such as *pneumocystis carinii* pneumonia (PCP) and tumors such as Kaposi's sarcoma (KS). It is known that the
5 mechanism of the destruction of the immune system is the cytopathic effect of HIV on CD4⁺ T_{HELPER} lymphocytes which are instrumental in proper functioning of cell mediated immunity.

AIDS and HIV infection initially involved homosexual men, intravenous drug users and
10 hemophiliacs in the United States and Europe. However, heterosexual infection has become common and rampant in Africa (particularly in Rwanda, Burundi, Zaire and Kenya), Brazil, India, Myanmar and Thailand. According to the World Health Organization, in excess of 10,000,000 people world-wide are estimated to be infected with the HIV. The available data indicates that almost all of these infected individuals would die for lack of an effective
15 treatment.

Humoral antibody response mediated by B Lymphocytes is usually strong in infected individuals with high antibody titres in those infected to the envelope proteins gp120, gp41 and *gag* proteins p24, p17 and p15. Unfortunately, this does not provide any protection
20 from continued and relentless infection and progression of the disease mainly due to cell-to-cell transmission of infection and inhibition of cytotoxic T lymphocytes perhaps by inhibition of the IL-2 (interleukin 2) signaling. The US National Institutes of Health recently abandoned phase III and phase IV trials of vaccines derived from various viral proteins of HIV because of disappointing results in earlier phases. Similarly, cellular
25 response against HIV is initially strong with an increase in cytotoxic ("killer") T

lymphocytes (CTL). Unfortunately, this breaks down soon after infection due to genetic variations in the *gag* CTL epitopes which allows the virus to escape CTL recognition. (Phillips RE et al; Nature 345:453, 1991)

- 5 Various drugs have also been approved for treatment of HIV infection such as zidovudine which interfere with the virus's nucleotide sequencing. While these were felt to be very promising in the earlier stages, development of resistance to them has caused a considerable amount of disappointment and frustration.
- 10 A variety of other approaches have been postulated. Professor Jonas Salk, in his commentary in Nature noted that as the disease progresses, titres of antibodies to gp41 and virus neutralizing antibody remain constant but the level of anti-p24 antibody which correlates with the presence of antibody dependent cell cytotoxicity (ADCC) and antibody to reverse transcriptase decline. He proposed treatment of symptomatic HIV infected
- 15 patients with sera from asymptomatic HIV infected patients. He further hypothesized that HIV immunogens given to HIV infected patients would be protective. (Salk J; Prospects for the control of AIDS by immunizing seropositive individuals. Nature 327:473-476, 1987)

Live-attenuated viruses and dead virions have been hypothesized but no researcher has yet

20 tried these either for prevention or treatment of HIV infection in humans in a meaningful manner.

SIV (Simian Immunodeficiency Virus) is a primate lentivirus with various strains that affect African green monkeys, macaque monkeys, sooty-mangabee monkeys, rhesus

25 monkeys and chimpanzees. SIV infection in monkeys is widely used to study the

physiology and pathology of the primate lentiviruses. A great deal of research has been done by attempting to infect monkeys with artificially created mutants of the SIV to determine their relative infectivity. Many of these studies focused on the role of the *nef* gene in the physiology of virus life cycle. The *nef* gene is present in all primate lentiviruses sequenced to-date. The gene consists of an open reading frame beginning within or immediately after the 3' end of the *env* gene and overlaps the U3 portion of the 3' long terminal repeat. The gene was previously named F, 3'-orf or B-orf. It is expressed *in vivo* as determined by antibodies to the *nef* gene product in infected individuals. Luria et al have shown that at least some *nef* gene products block the induction of IL-2 (interleukin 2) mRNA in lymphoid cells triggered by activating agents PMA, PHA and/or antibodies against CD3, TCR or CD2 (Luria S, Chambers I, Berg P; Proc Natl Acad Sci USA 88:5326, 1991). Kestler et al have found rapid reversion of stop codon point mutations in *nef* to open forms *in vivo*, demonstrating selective pressure for open, presumably functional forms of *nef*. (Kestler HW et al; Cell, 65:651, 1991) It was further shown that *nef* is necessary for vigorous virus replication in rhesus monkeys, for maintaining normal virus loads and for induction of the disease. Animals inoculated with *nef*-deletion mutants have remained disease free for at least 3 years while wild-type virus infected animals all developed AIDS and died. It has also been demonstrated that *nef* deletion increases viral replication but it is postulated that the responses to *nef* deletion are different *in vivo* and *in vitro*. (Gibbs JS and Desrosiers RC in Human Retroviruses, Cullen BR,ed, Oxford University Press, NY, 1993)

It became the first object of this invention, therefore, to produce an HIV virus clone by utilizing recombinant technology in which a substantial portion of the *nef* gene is deleted while preserving the remaining open reading frames, particularly *tat*, *pol*, *gag*, *env* and *vpr*.

It is a further object of this invention to inject patients infected with HIV with this *nef* deleted recombinant virus and provide a cure by means of one or more of

a) by allowing normal IL2 and IFN γ production in T_{HELPER} cells thus activating B lymphocytes and cytotoxic ("killer") T lymphocytes (CTL) to recognize HIV antigen displaying cells,

b) by continually activating, stimulating and maintaining a cell mediated immune response to wild-type HIV via cytotoxic T Lymphocytes (CTL),

c) and by competing with the wild-type HIV for potential hosts and thus increasing the likelihood of exposure of the wild-type HIV to humoral antibodies to gp120, gp41 and *gag* proteins.

The second object of this invention is to provide prophylactic immunization in high risk individuals such as commercial sex workers by treatment with the *nef* deleted mutant virus which is a subject of this invention by providing a line of cytotoxic T lymphocytes with specificity to cells expressing any of the HIV proteins and which would create a semi-permanent memory stems of CTLs lasting a long time. Infection by wild-type HIV would, in these individuals be handled quickly, efficiently and effectively.

20

SUMMARY OF THE INVENTION

A recombinant clone of HIV-1_{ELI} isolate with its *nef* open reading frame deleted was constructed from a plasmid vector by endonuclease cleaving at Nco I and Xho I sites and

filling in the open ends with an oligonucleotide. The resultant plasmid DNA was screened and transfected by using DEAE dextran into HuT 78 cell line. HIV virus propagation was confirmed by monitoring proteins gp41, p24, p17 and p15, by monitoring reverse transcriptase activity and by electron microscopic identification of virions. Virus particles were separated from supernatant medium and frozen in liquid nitrogen until use. For treatment of HIV infection, after baseline diagnostic procedures including confirmation of HIV infection and CD4-CD8 cell counts, a skin test for allergic reaction and an informed consent, approximately 200,000,000 virus particles will be injected intravenously. This will be followed by semimonthly monitoring of CD4 counts and a booster dose of another 200,000,000 virus particles intravenously. This will be followed by monthly monitoring of CD4 counts for one year. According to the invention, patients are expected to have a normal CD4 count in 6-9 months and will have restored immune systems in 1 year. For prevention of wild-type HIV infection in high risk populations, approximately 1,000,000 virus particles will be injected subcutaneously, the subjects observed for sufficient time to ensure absence of untoward effects such as an anaphylactic reaction. Immunity in this population will be ascertained by seroconversion and wild-type HIV infection can be diagnosed by utilizing enzyme linked immunosorbent assays for detection of antibodies to the *nef* gene product.

In another aspect, the present invention provides a therapeutic suspension for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in humans comprising isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I, wherein said viral particles are suspended in a

6a

pharmaceutically acceptable diluent and said suspension functions to increase or restore CD4⁺ lymphocyte levels to reduce the HIV-1 viral burden in HIV-1-infected subjects.

In another aspect, the present invention provides use of a therapeutic suspension comprising isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I, wherein said viral particles are suspended in a pharmaceutically acceptable diluent, for increasing or restoring CD4⁺ lymphocyte levels in human immunodeficiency virus type 1 (HIV-1)-infected subjects.

In another aspect, the present invention provides use of a therapeutic suspension comprising isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I, wherein said viral particles are suspended in a pharmaceutically acceptable diluent, for reducing the HIV-1 viral burden in HIV-1-infected subjects.

In another aspect, the present invention provides use of a therapeutic suspension comprising isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I, wherein said viral particles are suspended in a pharmaceutically acceptable diluent, for enhancing immunity against human immunodeficiency virus type 1 (HIV-1) infection in a subject.

6b

In another aspect, the present invention provides use of isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I and a pharmaceutically acceptable diluent, for preparing a therapeutic suspension for increasing or restoring CD4⁺ lymphocyte levels in human immunodeficiency virus type 1 (HIV-1)-infected subjects.

In another aspect, the present invention provides use of isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I and a pharmaceutically acceptable diluent, for preparing a therapeutic suspension for reducing the HIV-1 viral burden in HIV-1-infected subjects.

In another aspect, the present invention provides use of isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I and a pharmaceutically acceptable diluent, for preparing a therapeutic suspension for enhancing immunity against human immunodeficiency virus type 1 (HIV-1) infection in a subject.

DESCRIPTION OF THE PREFERRED EMBODIMENT

HuT 78 Cells, a human lymphoid cell line was obtained from the American Type Culture Collection (Rockville, MD) and propagated in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY) containing 10% heated (56°F, 30 minutes) calf serum (Sigma

Chemical Company, St. Louis, Missouri) and 10% interleukin 2 - a T cell growth factor (Meloy laboratories, Springfield, VA). Cells were grown on plastic tissue culture dishes (Falcon^{*}) and transferred using trypsin with EDTA (Gibco, Grand Island, NY). This cell line was inoculated with peripheral blood mononuclear cells (PBMCs) from an AIDS patient infected with the HIV-1_{ELI} strain. The PBMCs were first prepared by banding over Ficoll^{*}-diatrizoate (density, 1.077 to 1.080 g/ml at 20° C)(Pharmacia LKB Biotechnology, Uppsala, Sweden). The PBMCs were washed with RPMI 1640 medium, stimulated for 5 days with 1 µg/ml of phytohemagglutinin (Sigma Chemical Co., St. Louis, MO) and washed free of phytohemagglutinin prior to inoculation. The molecular cloning techniques were used as described by Maniatis T, Fritsch, EF et al (Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). By using a non-cutter restriction endonuclease of HIV-1_{ELI} (New England Biolabs, Beverly, MA) from total cell DNA of the infected cell line, integrated proviral DNA with flanking cellular sequences were cloned into the *Xba* I site of bacteriophage J1 (Promega Biotec, Madison, WI) giving rise to a recombinant phage clone λHXELI. A vector SP65gpt was constructed by ligating *Bam* HI-*Pvu* II fragment of plasmid pSV2gpt into the *Bam* HI - *Pvu* II sites of SP65 (Promega Biotec, Madison, WI). A 12.5 Kilobase (kb) *Hpa* I-*Xba* I fragment of the clone λHXELI was blunt-ended with Klenow fragment of DNA polymerase I and cloned into similarly blunt-ended *Bam* HI to *Eco* RI sites of vector SP65gpt. The resultant clone HXELIgpt had the HIV-1_{ELI} and xanthine guanine phosphoribosyl transferase (gpt) sequences in identical transcriptional orientation. The provirus containing plasmid vector was digested with *Nco* I (Boehringer Mannheim Biochemicals, Mannheim, Germany) and *Xho* I (New England Biolabs, Beverly, MA) restriction endonucleases followed by a filling in the ends with an oligonucleotide constructed on a Biosearch Cyclone synthesizer.

*Trademark

reverse transcriptase and dNTPs, followed by ligation of the blunt ends. Plasmids were screened by electrophoresis on 0.8% agarose gels (Sigma Chemicals, St. Louis, MO) for derivatives of HXELIgt containing *nef* deletion. The exact coordinates of the deletion were confirmed by DNA sequencing with chain terminating inhibitors of DNA polymerase

5 - 2',3'-dideoxy and arabinonucleoside analogues of the normal deoxynucleoside triphosphate (ddCTP was obtained from Collaborative Research, Inc., Waltham, MA, araATP and araCTP were obtained from P-L Biochemicals, Inc., Milwaukee, WI) as described by Sanger, F, Nicklsen, S et al (Proc Natl Acad of Sci 74:5463-5467, 1977). Heteroduplex DNA was subjected to ethanol precipitation and and resuspended in sterile

10 water. Serial dilutions of DNA were prepared to a final volume of 80 micL. To each sample of DNA was added 20 µL DEAE dextran (molecular weight 5×10^5) obtained from Pharmacia in a concentration of 2 mg/ml after sterilizing by autoclaving and 100 µL of two-fold concentrated serum-free Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY). The HuT 78 cells described above were transferred to fresh plates 24 hours

15 prior to transfection to ascertain an exponential growth. These growing cells were removed from plates with 0.1% trypsin with EDTA (Gibco, Grand Island, NY) in Tris-buffered isotonic saline at pH 7.2 (Sigma Chemicals, St. Louis, MO) , mixed with fresh Dulbecco's modified Eagle's medium containing heated calf serum as described above to inactivate the trypsin and counted with a Coulter counter. 6×10^5 cells were added to 2 ml Dulbecco's

20 modified Eagle's medium containing serum in 12 mm x 75 mm clear plastic tubes (Falcon #2058). The tubes were centrifuged at 5000 rpm for 1 minute. The medium was withdrawn carefully using a pipette with an aspirator. A 100 µL sample of the DNA dilution was added to each tube. The tubes were gently shaken and transferred to a 37°C CO₂ incubator for 1 hr. The rack was gently shaken every 15 minutes. At the end of the incubation, 2 ml of

fresh Dulbecco's modified Eagle's medium containing heated calf serum as described above was added to each tube, the tubes were shaken, centrifuged and the medium aspirated as described above. The cells were then resuspended in 2 ml of fresh Dulbecco's modified Eagle's medium containing heated calf serum as described above and incubated at 37°C in a 5% CO₂ incubator. The cultures were monitored for appearance of HIV-1 *gag* and *env* products p17, p24 and gp41, reverse transcriptase activity and virions as seen by electron microscopy as is readily known to those knowledgeable in the art. Virus containing supernatant of the cultures was filtered through a millipore filter (filter size 0.45µm, Millipore* Corp., Bedford, MA) and placed in sterile vials so as to contain about 200,000,000 virion particles per ml. The sterile vials were stored in liquid nitrogen.

EXAMPLE 1

Two volunteers (S1 and S2), both commercial sex workers in India became HIV positive in 1989. Since then, both have had a downhill course with diarrhoea, weight loss, candida and CMV infections. Their CD4 counts were 327 and 258 respectively. Families and friends of both had deserted them due to their HIV infection and they had almost no support structure left. After a detailed informed consent and a thorough discussion of all the risks involved with the use of the present invention, these individuals were given a physical, confirmatory Western Blot tests to ensure HIV status, baseline CD4-CD8 cell counts and a skin test for sensitivity to the viral suspension, both were given 1 ml of recombinant viral suspension containing approximately 200,000,000 virus particles intravenously. The patients were quarantined in an isolated facility and all personnel coming in contact with them used

*Trademark

communicable disease precautions. The patients' CD4 counts were recorded one month after the first injection and they were given a second injection of equal dose intravenously. Their CD4 counts were recorded once again, 4-6 weeks after the booster. The patients started gaining weight in approximately 4-6 weeks after the first injection and their CD4 counts increased as shown in the accompanying table. They became asymptomatic in 3 and 4.5 months respectively.

	Prior to Vaccine	After Vaccine& Booster
Patient S1	240/mm ³	1051/mm ³
Patient S2	385/mm ³	1233/mm ³

10

EXAMPLE 2

100 SCID (Severe Combined Immunodeficiency Syndrome) mice with human immune system transplanted were separated into control and experimental group of 50 mice each. The experimental group was infected with an intravenous injection of 1 million virions of the nef deleted virus subject of the preferred embodiment. 1 month after this injection, both the groups were infected with wild-type HIV-1 virions and infected lymphocytes. 1 month after the infection, 10 mice from each group were sacrificed and their lymphoid tissues examined. The pathologic examination revealed a severe loss of follicular dendritic cells, considerable syncytium formations and the peripheral blood with an average reduction of 38.6% in CD4 cell counts in the control group. The experimental group revealed minimal pathologic changes and no significant reduction in the CD4 cell counts. After 2 more

months had elapsed, 58% of the animals in the control group were dead as a result of immunodeficiency caused by the wild-type HIV-1 infection whereas no animals in the experimental group died as a result of immunodeficiency. This observation is statistically significant ($p < .001$). 20 animals from the experimental group were again infected with
5 wild-type HIV-1 as described above and again, there was no pathologic response.

Since the recombinant virus which is a subject of this invention has been found to be non-pathogenic and affording immunity from the CD4 cytotoxic effects of wild-type HIV as described above, the following protocol is established for prophylaxis against wild type
10 HIV infection in high risk individuals:

1. A thorough physical examination and education regarding HIV infection.
2. A detailed discussion of the risks of prophylaxis with recombinant *nef* deleted HIV virus and procurement of an informed consent. The discussion will include the inability to
15 diagnose wild-type HIV infections from standard tests and the need to perform a special ELISA (enzyme linked immunosorbent assay) to detect antibodies to the *nef* protein.
3. Approximately 1,000,000 virus particles suspended in 0.5 ml to be given subcutaneously.
4. Subjects will be observed for a sufficient time to ensure lack of untoward reactions such as an anaphylactic reaction.
- 20 5. Seroconversion will be monitored for successful immune response to the recombinant virus.

It is understood that the foregoing description and examples have been given merely by way of illustration and that modifications and variations may be made therein without
25 departing from the spirit and scope of the present invention.

CONCLUSION, RAMIFICATIONS & SCOPE

- 5 Even though just one potential use of a recombinant retrovirus has been described, the principle of the invention has many far reaching implications. The principle could be used broadly for prevention and treatment of other retroviral infections such as the leukemia caused by HTLV viruses. There may be other pathogenic retroviruses that have yet to be discovered in whom this principle could be used. It is certainly probable that this invention
- 10 could be modified to alter the location and extent of the gene deletion and/or expand the sites of deletions. It is also feasible to create a similar gene deletion by using alternative methods to those described in the preferred embodiment of the invention above.

CLAIMS

1. A therapeutic suspension for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in humans comprising isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I, wherein said viral particles are suspended in a pharmaceutically acceptable diluent and said suspension functions to increase or restore CD4⁺ lymphocyte levels to reduce the HIV-1 viral burden in HIV-1-infected subjects.

2. Use of a therapeutic suspension comprising isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I, wherein said viral particles are suspended in a pharmaceutically acceptable diluent, for increasing or restoring CD4⁺ lymphocyte levels in human immunodeficiency virus type 1 (HIV-1)-infected subjects.

3. Use of a therapeutic suspension comprising isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I, wherein said viral particles are suspended in a pharmaceutically acceptable diluent, for reducing the HIV-1 viral burden in HIV-1-infected subjects.

4. Use of a therapeutic suspension comprising isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1

molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I, wherein said viral particles are suspended in a pharmaceutically acceptable diluent, for enhancing immunity against human immunodeficiency virus type 1 (HIV-1) infection in a subject.

5. Use of isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I and a pharmaceutically acceptable diluent, for preparing a therapeutic suspension for increasing or restoring CD4⁺ lymphocyte levels in human immunodeficiency virus type 1 (HIV-1)-infected subjects.

6. Use of isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I and a pharmaceutically acceptable diluent, for preparing a therapeutic suspension for reducing the HIV-1 viral burden in HIV-1-infected subjects.

7. Use of isolated and purified HIV-1 *nef*-deficient viral particles prepared from cells transfected with a recombinant HIV-1 molecular clone having a *nef*-deletion between the endonuclease cleavage sites *Nco* I and *Xho* I and a pharmaceutically acceptable diluent, for preparing a therapeutic suspension for enhancing immunity against human immunodeficiency virus type 1 (HIV-1) infection in a subject.